Study guide

8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

Key Takeaways Explain This Topic AI

Clinical trials progress through four distinct phases: Phase I evaluates safety, PK/PD, and MTD/RP2D; Phase II evaluates preliminary efficacy (ORR); Phase III compares efficacy against standard of care in large randomized cohorts; Phase IV provides post-marketing safety surveillance.

Bioethical principles governing oncology clinical trials (Belmont Report) include Respect for Persons, Beneficence, and Justice, overseen by Institutional Review Boards (IRBs) through mandatory informed consent and continuous safety monitoring.

Adverse events are graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0) on a 1-5 scale (Grade 1 Mild to Grade 5 Death), with Serious Adverse Events (SAEs) requiring expedited reporting within 24 hours.

RECIST 1.1 defines objective tumor response in solid tumors based on target lesion sum of diameters (SoD): Complete Response (CR = disappearance of all target lesions and lymph nodes <10mm), Partial Response (PR = ≥30% decrease in SoD), Progressive Disease (PD = ≥20% increase in SoD + ≥5mm absolute increase OR new lesions), and Stable Disease (SD).

Immune-related Response Criteria (iRECIST) introduces unconfirmed progressive disease (iUPD) to account for pseudoprogression, requiring confirmation scans 4 to 8 weeks later prior to classifying true immune progressive disease (iCPD).

Last updated: August 2026

Clinical Trials, Research Protocols & Response Evaluation (RECIST)

Clinical research drives the development of novel antineoplastic therapies, translating bench science into clinical practice. Advanced Practice Registered Nurses (APRNs) function as principal investigators, co-investigators, research nurse specialists, and advanced clinicians evaluating patients on clinical trials. Mastery of trial phases, ethical frameworks, adverse event grading, protocol compliance, and standardized objective response criteria (RECIST 1.1 and iRECIST) is essential for maintaining scientific integrity and patient safety.

1. Clinical Trial Phases & Experimental Designs

Oncology drug development follows a sequential four-phase clinical trial architecture:

Trial Phase Primary Objective Cohort Size Typical Study Design & Endpoints

Phase I Evaluate safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). 15–30 patients Dose-escalation design (classic 3 + 3 3+3 3 + 3 design, accelerated titration, or Bayesian optimal interval [BOIN] design). Enrollment across tumor types.

Phase II Assess preliminary therapeutic efficacy in specific tumor types and expand safety database. 30–100 patients Single-arm or randomized. Endpoints: Overall Response Rate (ORR), Duration of Response (DoR), Progression-Free Survival (PFS).

Phase III Demonstrate definitive efficacy superiority or non-inferiority compared to current Standard of Care (SOC). 300–1,000+ patients Large Randomized Controlled Trials (RCTs), prospective, multi-center, double-blind or open-label. Primary endpoints: Overall Survival (OS), PFS.

Phase IV Post-marketing surveillance; monitor long-term safety, rare toxicities, and real-world effectiveness. Thousands of patients Observational, post-approval registries, real-world evidence (RWE) studies.

Novel Master Protocol Designs

Basket Trials : Test a single targeted therapy against a specific genomic mutation across multiple different histology tumor types (e.g., larotrectinib in NTRK fusion-positive solid tumors).

Umbrella Trials : Test multiple different targeted therapies within a single tumor type, matched to individual patient biomarker profiles (e.g., non-small cell lung cancer umbrella protocols).

Platform Trials : Multi-arm, perpetual trials allowing candidate drugs to enter or leave the infrastructure based on interim efficacy algorithms.

2. Bioethics, IRB Oversight & Informed Consent

Human subject protection in oncology research is governed by international ethical frameworks (Declaration of Helsinki, Belmont Report) and federal regulations (FDA Title 21 CFR, Common Rule 45 CFR 46).

Core Ethical Principles (Belmont Report)

Respect for Persons : Asserts individual autonomy. Requires voluntary informed consent without coercion or undue influence. Special protections must be extended to vulnerable populations (e.g., pediatric patients, prisoners, cognitively impaired, economically disadvantaged).

Beneficence : Obligates researchers to maximize potential benefits while minimizing potential risks ("Do no harm").

Justice : Mandates equitable selection of research subjects, ensuring fair distribution of research risks and benefits without demographic bias.

Institutional Review Board (IRB) Principles

Every clinical trial protocol, consent form, patient questionnaire, and advertisement must receive prospective review and approval from an accredited Institutional Review Board (IRB) .

Informed Consent Process : Informed consent is an ongoing communication process, not merely signing a document. Patients must be informed of potential risks, benefits, alternative treatments (including SOC and palliative care), and their absolute right to withdraw consent at any time without compromising standard medical care.

Protocol amendments, safety updates, and un-blinding requests require immediate IRB re-approval.

3. CTCAE v5.0 Adverse Event Grading & SAE Reporting

The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) provides standardized definitions and severity grading for adverse events (AEs) occurring in oncology clinical trials.

Severity Grading Scale (Grades 1 to 5)

Grade 1 (Mild) : Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

Grade 2 (Moderate) : Minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADLs).

Grade 3 (Severe) : Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADLs.

Grade 4 (Life-Threatening) : Life-threatening consequences; urgent intervention indicated.

Grade 5 (Death) : Death related to the adverse event.

Serious Adverse Event (SAE) Reporting Rules

An Adverse Event (AE) is any untoward medical occurrence in a patient administered a pharmaceutical product, regardless of causal relationship. An AE is defined as a Serious Adverse Event (SAE) if it results in any of the following outcomes:

  • Patient death
  • Life-threatening event
  • Inpatient hospitalization or prolongation of existing hospitalization
  • Persistent or significant disability/incapacity
  • Congenital anomaly / birth defect

APRN Protocol Action : All SAEs mandate expedited reporting within 24 hours of discovery to the trial sponsor, principal investigator, and IRB, regardless of attributed drug relationship.

4. Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

RECIST 1.1 provides standardized anatomical imaging criteria (CT/MRI) to assess objective tumor response in solid tumor clinical trials.

Baseline Target vs. Non-Target Lesion Selection

Target Lesions : Maximum of 5 total lesions (and maximum of 2 lesions per organ ) representative of all involved organs. Must be measurable at baseline:

Non-Nodal Lesions : Longest diameter ≥ 10 mm \ge 10\text{ mm} ≥ 10 mm on CT slice.

Pathological Lymph Nodes : Short axis ≥ 15 mm \ge 15\text{ mm} ≥ 15 mm on CT slice.

Non-Target Lesions : All other lesions, including non-measurable disease (e.g., bone metastases, leptomeningeal disease, ascites, pleural effusion, or nodes with short axis 10 – 14 mm 10–14\text{ mm} 10–14 mm ).

Categorical Tumor Response Criteria (Target Lesions) Sum of Diameters (SoD) = ∑ Longest Diameters of Non-Nodal Targets + ∑ Short Axes of Target Nodes \text{Sum of Diameters (SoD)} = \sum \text{Longest Diameters of Non-Nodal Targets} + \sum \text{Short Axes of Target Nodes} Sum of Diameters (SoD) = ∑ Longest Diameters of Non-Nodal Targets + ∑ Short Axes of Target Nodes

Response Category RECIST 1.1 Anatomical Criteria

Complete Response (CR) Disappearance of all target lesions. All pathological lymph nodes must decrease to short axis < 10 mm < 10\text{ mm} < 10 mm .

Partial Response (PR) At least a 30% decrease in the Sum of Diameters (SoD) of target lesions, taking as reference the baseline SoD .

Progressive Disease (PD) At least a 20% increase in the SoD of target lesions, taking as reference the smallest SoD recorded on study (nadir) , AND an absolute increase of at least 5 mm . The appearance of one or more new lesions automatically constitutes PD.

Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SoD (nadir).

5. Immune-Related Response Criteria (iRECIST)

Cancer immunotherapies (checkpoint inhibitors) can induce atypical response patterns, such as pseudoprogression —an initial increase in tumor burden or appearance of new lesions caused by intratumoral infiltration of activated lymphocytes, followed by delayed tumor regression. Baseline Imaging & Target Lesion SoD Calculated

  • │
  • ▼
  • Follow-Up Imaging Demonstrates >= 20% Increase in SoD or New Lesion
  • │
  • ├── Standard RECIST 1.1: Classify as Progressive Disease (PD) -> Stop Trial Drug
  • │
  • └── iRECIST Guidelines: Classify as Immune Unconfirmed Progressive Disease (iUPD)
  • │
  • ▼
  • Continue Immunotherapy & Re-Image in 4 to 8 Weeks
  • │
  • ├── Further Increase in SoD / New Lesions: Classify as iCPD (Confirmed PD) -> Discontinue
  • └── Tumor Shrinkage / Stabilization: Classify as Pseudoprogression (PR/SD) -> Continue

iUPD (Immune Unconfirmed Progressive Disease) : Assigned upon initial observation of progression criteria. If the patient remains clinically stable, immunotherapy is continued, and a confirmation scan is performed 4 to 8 weeks later .

iCPD (Immune Confirmed Progressive Disease) : Assigned if the follow-up scan demonstrates further increase in tumor size or new lesions, confirming true progressive disease.

Loading diagram... RECIST 1.1 vs iRECIST Response Assessment Algorithm